Oppenheimer initiated coverage of Guardian Pharmacy (GRDN) with an Outperform rating and $30 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy price target raised to $30 from $28 at Truist
- Guardian Pharmacy management to meet with Truist
- Guardian Pharmacy Highlights Strategic Initiatives in ALF Market
- Guardian Pharmacy Services Reports Strong Q2 2025 Results
- Guardian Pharmacy reports Q2 adjusted EPS 23c, two estimates 22c